Get the Stockscreener App
1.85
5.71%
0.10
Pre-market:
1.85
Nexalin Technology Inc stock is traded at $1.85, with a volume of 43,302.
It is up +5.71% in the last 24 hours and down -20.94% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$1.75
Open:
$1.79
24h Volume:
43,302
Relative Volume:
0.21
Market Cap:
$22.46M
Revenue:
$128.60K
Net Income/Loss:
$-4.60M
P/E Ratio:
-2.9365
EPS:
-0.63
Net Cash Flow:
$-3.74M
1W Performance:
+9.56%
1M Performance:
-20.94%
6M Performance:
-13.95%
1Y Performance:
+30.28%
1-Day Range:
$1.71
$1.88
1-Week Range:
$1.6606
$1.8916
52-Week Range:
$0.53
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
1.85 | 22.46M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
129.38 | 227.16B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.14 | 140.69B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
361.05 | 132.32B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.30 | 105.94B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.13 | 41.90B | 5.72B | 4.17B | 259.90M | 6.97 |
Nexalin Technology Inc Stock (NXL) Latest News
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia - GlobeNewswire
Nexalin Technology Receives IRB Approval In Brazil And Begins Clinical Trial For Anxiety And Insomnia - marketscreener.com
Nexalin's Neurostimulation Device Begins Phase II Trial for Anxiety and Insomnia Treatment in Brazil - Stock Titan
Nexalin Technology Inc May Offer, Sell Up To $50 Mln Of Common Stock From Time To Time In One Or More Offerings - marketscreener.com
Nexalin Technology (NXL) Launches Advanced Virtual Clinic for Mi - GuruFocus
Nexalin Technology Announces Completion of Phases One - GlobeNewswire
Advanced AI Virtual Clinic Powers Groundbreaking Military PTSD Study: Nexalin's New Digital Health Platform - Stock Titan
Nexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical Devices - Nasdaq
Nexalin Technology Expresses Strong Support for Health Tech - GlobeNewswire
Medicare May Cover AI Mental Health Devices as Nexalin Backs New Bill | NXL Stock News - Stock Titan
Nexalin Technology appoints new accounting firm By Investing.com - Investing.com Canada
Nexalin Technology appoints new accounting firm - Investing.com
Nexalin secures patent on brain stimulation method for substance use disorders - Yahoo
Nexalin Secures Patent for Intracranial Stimulation Technology - marketscreener.com
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders - The Manila Times
Nexalin Technology Secures USPTO Patent for Deep - GlobeNewswire
Game-Changing Patent: Nexalin's Brain Stimulation Tech Takes On $35B Addiction Treatment Market - Stock Titan
Nexalin begins clinical trial for brain stimulation therapy By Investing.com - Investing.com South Africa
Nexalin begins clinical trial for brain stimulation therapy - Investing.com
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial - The Manila Times
Revolutionary Brain Treatment: Nexalin Launches PTSD Trial at UCSD with AI-Powered Home Therapy - Stock Titan
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3 - GlobeNewswire
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3 - The Manila Times
Revolutionary Brain Tech Targets $537B Market: Nexalin CEO Reveals Growth Strategy - Stock Titan
Nexalin Technology (NASDAQ:NXL) Upgraded to “Buy” at Maxim Group - Defense World
Nexalin Technology (NASDAQ:NXL) Upgraded at Maxim Group - The AM Reporter
Maxim Group Upgrades Nexalin Technology (NXL) - Nasdaq
Nexalin Technology, Inc. SEC 10-K Report - TradingView
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Weatherford Democrat
Nexalin Technology’s Senior VP Makes a Bold Stock Purchase - TipRanks
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock - Investing.com India
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock By Investing.com - Investing.com UK
Nexalin Technology Stock Price, Quotes and Forecasts | NASDAQ:NXL - Benzinga
Nexalin Technology, Inc. Receives USPTO Notice of Allowance for Patent on Innovative Treatment Method for Opioid and Substance Use Disorders - Nasdaq
Nexalin Technology Receives Notice of Allowance from the - GlobeNewswire
Could This Newly Patented Technology Transform How We Treat Addiction? - StockTitan
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD - Yahoo Finance
Nexalin Technology Announces Initiation of Patient - GlobeNewswire
Nexalin Technology, Inc. Launches Clinical Trial for HALO™ Clarity Device to Treat Mild Traumatic Brain Injury and PTSD at UCSD - Nasdaq
Nexalin Technology announces initiation of patient recruitment in UCSD study - TipRanks
Can Nexalin's Brain Stimulation Technology Transform PTSD Treatment? UCSD Trial Now Recruiting Patients - StockTitan
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board - EIN News
Nexalin Technology Appoints General Wesley Clark to Military & Government Advisory Board - citybiz
Can NATO's Former Supreme Commander Help Nexalin Crack the Military Mental Health Market? - StockTitan
Nexalin Secures UCSD IRB Approval For Use Of HALO Clarity In PTSD And MTBI Clinical Studies - Nasdaq
Nexalin Technology Announces UCSD IRB Approval for use of - GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment - Marketscreener.com
Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval - Marketscreener.com
Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD - Nasdaq
Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSDPotential Breakthrough for Veterans - StockTitan
10,000 Shares in Nexalin Technology, Inc. (NASDAQ:NXL) Bought by Kingsview Wealth Management LLC - Defense World
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nexalin Technology Inc Stock (NXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
3.10 |
1,000 |
3,100 |
155,793 |
| Owens David | Chief Medical Officer |
Feb 04 '25 |
Buy |
2.98 |
1,000 |
2,980 |
154,793 |
| Owens David | Chief Medical Officer |
Jan 28 '25 |
Buy |
2.70 |
1,500 |
4,050 |
153,793 |
| Owens David | Chief Medical Officer |
Jan 13 '25 |
Buy |
2.50 |
2,000 |
5,000 |
151,293 |
| Owens David | Chief Medical Officer |
Jan 23 '25 |
Buy |
2.70 |
1,000 |
2,700 |
152,293 |
| Owens David | Chief Medical Officer |
Oct 28 '24 |
Buy |
2.19 |
500 |
1,095 |
148,293 |
| Owens David | Chief Medical Officer |
Aug 13 '24 |
Buy |
0.95 |
1,000 |
950 |
147,793 |
| Owens David | Chief Medical Officer |
Jun 28 '24 |
Buy |
1.75 |
1,000 |
1,750 |
146,793 |
| Owens David | Chief Medical Officer |
Jun 18 '24 |
Buy |
0.71 |
1,619 |
1,149 |
145,793 |
| Owens David | Chief Medical Officer |
Jun 10 '24 |
Buy |
0.64 |
3,000 |
1,920 |
144,174 |
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):